199 related articles for article (PubMed ID: 22126283)
41. The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia.
Wang G; Zhang W; Ren J; Zeng Y; Dang X; Tian X; Yu W; Li Z; Ma Y; Yang P; Lu J; Zheng J; Lu B; Xu J; Liang A
Oncogene; 2024 Jun; 43(25):1900-1916. PubMed ID: 38671157
[TBL] [Abstract][Full Text] [Related]
42. A MENage à Trois in leukemia.
Roudaia L; Speck NA
Cancer Cell; 2008 Jul; 14(1):3-5. PubMed ID: 18598937
[TBL] [Abstract][Full Text] [Related]
43. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
44. [Mechanism of A New DOT1L Inhibitor EPZ-5676 and Its Research Progress -Review].
Li LH; Wang J; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1909-1912. PubMed ID: 28024519
[TBL] [Abstract][Full Text] [Related]
45. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
46. DOT1L and H3K79 Methylation in Transcription and Genomic Stability.
Wood K; Tellier M; Murphy S
Biomolecules; 2018 Feb; 8(1):. PubMed ID: 29495487
[TBL] [Abstract][Full Text] [Related]
47. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L.
Stein EM; Tallman MS
Curr Opin Hematol; 2015 Mar; 22(2):92-6. PubMed ID: 25635757
[TBL] [Abstract][Full Text] [Related]
48. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
[TBL] [Abstract][Full Text] [Related]
49. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
[TBL] [Abstract][Full Text] [Related]
50. Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale.
Stumpel DJ; Schotte D; Lange-Turenhout EA; Schneider P; Seslija L; de Menezes RX; Marquez VE; Pieters R; den Boer ML; Stam RW
Leukemia; 2011 Mar; 25(3):429-39. PubMed ID: 21116279
[TBL] [Abstract][Full Text] [Related]
51. Synthesis and Biological Activity of a Cytostatic Inhibitor of MLLr Leukemia Targeting the DOT1L Protein.
Bon C; Si Y; Pernak M; Barbachowska M; Levi-Acobas E; Cadet Daniel V; Jallet C; Ruzic D; Djokovic N; Djikić T; Nikolic K; Halby L; Arimondo PB
Molecules; 2021 Aug; 26(17):. PubMed ID: 34500733
[TBL] [Abstract][Full Text] [Related]
52. A new rearrangement giving rise to a very rare MLL-MLLT10 fusion mRNA in an infant acute myeloid leukemia.
Burillo-Sanz S; Morales-Camacho R; Vargas MT; Carrillo E; Pérez-Soto I; García-Lozano JR
Cancer Genet; 2015 Mar; 208(3):101-2. PubMed ID: 25475940
[No Abstract] [Full Text] [Related]
53. Reprogramming of the Epigenome by MLL1 Links Early-Life Environmental Exposures to Prostate Cancer Risk.
Wang Q; Trevino LS; Wong RL; Medvedovic M; Chen J; Ho SM; Shen J; Foulds CE; Coarfa C; O'Malley BW; Shilatifard A; Walker CL
Mol Endocrinol; 2016 Aug; 30(8):856-71. PubMed ID: 27219490
[TBL] [Abstract][Full Text] [Related]
54. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
Chopra M; Bohlander SK
Cancer Genet; 2015 May; 208(5):192-205. PubMed ID: 25592767
[TBL] [Abstract][Full Text] [Related]
55. MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.
Kühn MW; Hadler MJ; Daigle SR; Koche RP; Krivtsov AV; Olhava EJ; Caligiuri MA; Huang G; Bradner JE; Pollock RM; Armstrong SA
Haematologica; 2015 May; 100(5):e190-3. PubMed ID: 25596271
[No Abstract] [Full Text] [Related]
56. Histone Modifications Regulate the Developmental Expression of Human Hepatic UDP-Glucuronosyltransferase 1A1.
Nie YL; Meng XG; Liu JY; Yan L; Wang P; Bi HZ; Kan QC; Zhang LR
Drug Metab Dispos; 2017 Dec; 45(12):1372-1378. PubMed ID: 29025858
[TBL] [Abstract][Full Text] [Related]
57. PAFc, a key player in MLL-rearranged leukemogenesis.
Tan J; Muntean AG; Hess JL
Oncotarget; 2010 Oct; 1(6):461-5. PubMed ID: 21037944
[TBL] [Abstract][Full Text] [Related]
58. When epigenetics kills: MLL fusion proteins in leukemia.
Slany RK
Hematol Oncol; 2005 Mar; 23(1):1-9. PubMed ID: 16118769
[TBL] [Abstract][Full Text] [Related]
59. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
[TBL] [Abstract][Full Text] [Related]
60. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
Gröschel S; Schlenk RF; Engelmann J; Rockova V; Teleanu V; Kühn MW; Eiwen K; Erpelinck C; Havermans M; Lübbert M; Germing U; Schmidt-Wolf IG; Beverloo HB; Schuurhuis GJ; Ossenkoppele GJ; Schlegelberger B; Verdonck LF; Vellenga E; Verhoef G; Vandenberghe P; Pabst T; Bargetzi M; Krauter J; Ganser A; Valk PJ; Löwenberg B; Döhner K; Döhner H; Delwel R
J Clin Oncol; 2013 Jan; 31(1):95-103. PubMed ID: 23008312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]